首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   72319篇
  免费   8430篇
  国内免费   313篇
耳鼻咽喉   800篇
儿科学   1707篇
妇产科学   2973篇
基础医学   7548篇
口腔科学   1668篇
临床医学   20953篇
内科学   13588篇
皮肤病学   902篇
神经病学   5863篇
特种医学   2020篇
外科学   7666篇
综合类   412篇
一般理论   46篇
预防医学   5658篇
眼科学   880篇
药学   3708篇
  1篇
中国医学   61篇
肿瘤学   4608篇
  2023年   1100篇
  2022年   614篇
  2021年   1413篇
  2020年   1388篇
  2019年   1210篇
  2018年   2318篇
  2017年   2427篇
  2016年   2686篇
  2015年   2815篇
  2014年   3301篇
  2013年   4355篇
  2012年   4301篇
  2011年   4761篇
  2010年   3474篇
  2009年   3548篇
  2008年   4035篇
  2007年   4227篇
  2006年   3884篇
  2005年   3811篇
  2004年   3508篇
  2003年   3258篇
  2002年   2962篇
  2001年   991篇
  2000年   697篇
  1999年   1001篇
  1998年   1174篇
  1997年   1160篇
  1996年   1074篇
  1995年   943篇
  1994年   738篇
  1993年   666篇
  1992年   551篇
  1991年   538篇
  1990年   512篇
  1989年   475篇
  1988年   392篇
  1987年   386篇
  1986年   369篇
  1985年   417篇
  1984年   340篇
  1983年   299篇
  1982年   294篇
  1981年   273篇
  1980年   212篇
  1979年   248篇
  1978年   219篇
  1977年   227篇
  1976年   194篇
  1975年   169篇
  1972年   154篇
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
1.
Die Anaesthesiologie - Phantomschmerzen haben eine hohe Prävalenz nach Majoramputationen und sind mit einer zusätzlichen Einschränkung der Lebensqualität verbunden....  相似文献   
2.
3.
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs.  相似文献   
4.
Introduction: The Hedgehog (HH) pathway constitutes a collection of signaling molecules which critically influence embryogenesis. In adults, however, the HH pathway remains integral to the proliferation, maintenance, and apoptosis of adult stem cells including hematopoietic stem cells.

Areas covered: We discuss the current understanding of the HH pathway as it relates to normal hematopoiesis, the pathology of acute myeloid leukemia (AML), the rationale for and data from combination therapies including HH pathway inhibitors, and ultimately the prospects that might offer promise in targeting this pathway in AML.

Expert opinion: Efforts to target the HH pathway have been focused on impeding this disposition and restoring chemosensitivity to conventional myeloid neoplasm therapies. The year 2018 saw the first approval of a HH pathway inhibitor (glasdegib) for AML, though for an older population and in combination with an uncommonly-used therapy. Several other clinical trials with agents targeting modulators of HH signaling in AML and MDS are underway. Further study and understanding of the interplay between the numerous aspects of HH signaling and how it relates to the augmented survival of AML will provide a more reliable substrate for therapeutic strategies in patients with this poor-risk disease.  相似文献   

5.
Despite common experiences of identity damage, decline, and deterioration, many brain injury survivors succeed in reconstructing robust identities in the wake of injury. Yet, while this accomplishment greatly benefits survivors’ quality of life, little is known about how positive identity work might be facilitated or enhanced in therapeutic institutions. Drawing on data from a women’s self-help group, we argue that an egalitarian, reflective, strength-focused, and gender-segregated environment can provide female ABI (acquired brain injury) survivors with a fertile scene for identity enhancement and offer unique opportunities for collective identity development. Sociolinguistic interactional analysis revealed four types of positive identity work undertaken within the group: constructing competent selves; tempering the threat of loss and impairment; resisting infantilisation and delegitimisation; and asserting a collective gender identity. This identity work was facilitated by specific programme attributes and activities and contributed to the global project of decentring disability and destigmatising impairments and losses. We call for increased attention to identity issues in brain injury rehabilitation and argue that gender-segregated programming can provide a unique space for female survivors to construct empowering individual and collective identities after injury.  相似文献   
6.
7.
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号